Amitriptyline-Grindeks Tablets 25 mgComposition:

Active ingredient:

Each coated tablet contains 25 mg of amitriptyline hydrochloride.

Excipients:
Coated 25 mg tablets contain lactose, corn starch, polyvinylpyrrolidone, silicon dioxide, magnesium stearate; coating: blue dye - Opadry II Blue, carnauba wax.

Indications for use:

Use only as directed by a physician.

• Depression of any etiology. Particularly effective in depressive states accompanied by anxiety due to its sedative effect;

• Mixed emotional disorders and behavioral disturbances; phobic fears;

• Childhood enuresis (except in children with hypotonic bladder);

• Psychogenic anorexia, bulimia nervosa;

• Chronic pain syndrome (neurogenic in nature), migraine prophylaxis.

Contraindications:

• Decompensated heart failure;

• Acute and recovery phase of myocardial infarction;

• Cardiac conduction disturbances;

• Stage III hypertension;

• Severe liver and kidney diseases with marked functional impairment;

• Blood disorders;

• Active peptic ulcer disease of the stomach and duodenum;

• Prostatic hypertrophy;

• Bladder atony;

• Pylorostenosis, paralytic intestinal obstruction;

• Concurrent treatment with monoamine oxidase inhibitors (MAOIs);

• Pregnancy, breastfeeding;

• Children under 6 years of age (injectable forms are for 12 years and older);

• Hypersensitivity to amitriptyline.

Method of administration and dosage:

Administer orally (during or after meals).

The initial daily oral dose is 50-75 mg (25 mg 2-3 times a day), gradually increasing by 25-50 mg until the desired antidepressant effect is achieved. The optimal therapeutic daily dose is 150-200 mg (the largest part of the dose is taken at night). For treatment-resistant severe depression, doses may be increased up to 300 mg or more, up to the maximum tolerated dose (the maximum dose for outpatients is 150 mg/day). In such cases, it is advisable to start treatment with intramuscular or intravenous administration with higher initial doses and faster dose escalation under somatic condition monitoring.
After a stable antidepressant effect is achieved, doses are gradually and slowly reduced over 2-4 weeks. If signs of depression appear during dose reduction, it is necessary to return to the initial dose.
If the patient's condition does not improve after 3-4 weeks of treatment, further continuation is not recommended.
For elderly patients with mild disorders in outpatient practice, doses are 25-50-100 mg (maximum) divided or once daily at bedtime.
For children over 6 years with enuresis, 12.5-25 mg at bedtime (the dose should not exceed 2.5 mg/kg of body weight).
For migraine prophylaxis and neurotic chronic pain (including prolonged headaches), 12.5-25 mg up to 100 mg daily.

Storage conditions:

Store in a dry, dark place at a temperature not exceeding 25°C. Keep out of reach of children!